⚕ GalenOps CRO console
← SITE008 (KOR)

SITE008-0022

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE008 (KOR) (Dr. Kim) · consented 2022-03-08
Adverse events
9
Serious AEs
0
Open data queries
0
Luna dropout signal
–

Adverse events

moderate assessed 2026-08-18

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-06-24 (study day 90); relationship: N

severe assessed 2026-08-18

Grade 3 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-07-18 (study day 114); relationship: N

mild assessed 2026-08-18

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-09-12 (study day 170); relationship: N

moderate assessed 2026-08-18

Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-09-16 (study day 174); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-01-06 (study day 286); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-23 (study day 334); relationship: N

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-03-19 (study day 358); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-10-10 (study day 563); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-12-05 (study day 619); relationship: N

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.